NCT00403650

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.

Detailed description

Pulmonary hypertension has been described in sarcoidosis. It can be a significant problem, not responsive to treatment with anti-inflammatory drugs for the sarcoidosis (1;2). Inhaled iloprost has been approved for treatment of pulmonary hypertension (3). We propose to study the effectiveness of inhaled iloprost for sarcoidosis associated pulmonary hypertension (SAPAH). This is an open label trial, with patients receiving 16 weeks of therapy. Clinical and hemodynamic outcome of therapy will be assessed.

Conditions

• Sarcoidosis
• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	Iloprost	Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day

Timeline

• Start date: 2006-11-01
• Primary completion: 2008-07-01
• Completion: 2008-09-01
• First posted: 2006-11-27
• Last updated: 2013-04-12

Locations

1 site across 1 country: United States